ACADIA Pharmaceuticals
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.6 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.17% +0.60pp
- Institutions
- 428 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 24.83% |
| Stephen Davis | Former Chief Executive Officer | 0.26% |
| Julian Baker | Independent Director | 0.06% |
| Mark Schneyer | Chief Financial Officer | 0.04% |
| Daniel Soland | Former Independent Director | 0.03% |
| Edmund Harrigan | Independent Director | 0.02% |
| Elizabeth Garofalo | Independent Director | 0.02% |
| Adora Ndu | Independent Director | 0.02% |
| Laura Brege | Independent Director | 0.01% |
| Elizabeth H. Thompson | Former Head of Research & Development | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-29 | Mark Schneyer | Chief Financial Officer | Automatic Disposition | -3,321 | $20.88 |
| 2026-10-14 | Mark Schneyer | Chief Financial Officer | Other Acquisition | +6,815 | -- |
| 2026-08-05 | Mark Schneyer | Chief Financial Officer | Derivative Exercise and Sale | -20,141 | $17.84–29.34 |
| 2026-08-04 | Mark Schneyer | Chief Financial Officer | Intent to Sell (Form 144) | -5,849 | $27.15 |
| 2026-07-29 | Elizabeth H. Thompson | Former Head of Research & Development | Derivative Exercise and Sale | -16,558 | $26.13–26.17 |
| 2026-07-28 | Elizabeth H. Thompson | Former Head of Research & Development | Derivative Exercise and Retained | +15,714 | -- |
| 2026-06-25 | James Kihara | Officer | Automatic Disposition | -11,421 | $26.08 |
| 2026-05-28 | Laura Brege | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Laura Brege | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | Laura Brege | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | Julian Baker | Independent Director | Other Derivative Acquisition | +64,016 | $21.66 |
| 2026-05-28 | Edmund Harrigan | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Edmund Harrigan | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | Edmund Harrigan | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | James Daly | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | James Daly | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
| 2026-05-28 | James Daly | Independent Director | Derivative Exercise and Retained | +8,107 | -- |
| 2026-05-28 | Baker Bros. Advisors LP | -- | Other Acquisition | +37,244 | -- |
| 2026-05-28 | Jonathan Poole | Independent Director | Other Derivative Acquisition | +9,311 | -- |
| 2026-05-28 | Jonathan Poole | Independent Director | Other Derivative Acquisition | +16,004 | $21.66 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ACADIA Pharmaceuticals discussion 0 comments